Raising Awareness for Eosinophilic Asthma

Throughout September, drivers and pedestrians in the Detroit suburbs may have noticed bold magenta billboards carrying a simple but important message: “Not all asthma is the same.”

The American Partnership for Eosinophilic Disorders (APFED) launched this awareness campaign to help people recognize a lesser-known but serious form of asthma—eosinophilic asthma—and to encourage conversations that lead to earlier diagnosis and more personalized care.

Spotlighting an Overlooked Condition

Eosinophilic asthma (often called eos asthma) is driven by high levels of eosinophils—white blood cells that cause inflammation in the airways. While symptoms can look similar to other forms of asthma, this subtype is often more severe and less responsive to standard asthma treatments. Persistent or hard-to-control asthma deserves a closer look.

September’s billboard campaign in Michigan was complementary to our social media campaign in 2025 to help people with asthma ask important questions in clinic, especially those whose asthma is uncontrolled.

Keeping the Momentum Going This Fall

Even though the billboards have come down, the message remains vital as we head into fall—when cooler weather and seasonal triggers can make asthma symptoms worse. This is an ideal time for patients to review their asthma management plans with their healthcare providers and ask:

• Could my asthma be eosinophilic?
• Should I have a blood test for eosinophils?
• Are there new treatments that might help me breathe easier?

APFED’s work in Michigan, supported by an educational grant from AstraZeneca, is part of a broader effort to bring education and support to those affected by eosinophil-associated diseases nationwide. From awareness campaigns to patient resources, APFED continues to empower individuals and families to seek answers and advocate for better care.

To learn more about eosinophilic asthma or to access educational materials for your community or clinic, visit apfed.org/asthma or eosasthma.org.